Biogen (BIIB) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biogen (BIIB) has outperformed Repligen (RGEN) over the past year, gaining 44.7% versus a gain of 8.6%. Over five years, BIIB leads with a -22.3% price change compared with -38.6% for RGEN. Biogen is the larger company by market cap ($33.37 billion vs $10.99 billion), about 3.0 times the size, while Repligen is growing revenue faster (+16.4% vs +2.2%).
On valuation, Biogen trades at a lower forward P/E (13.7x vs 65.4x for Repligen). Biogen converts more of its revenue into profit, with a net margin of 13.1% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | RGEN |
|---|---|---|
| Share price | $225.85 | $173.06 |
| Market cap | $33.37B | $10.99B |
| 1-day change | +3.39% | +5.62% |
| YTD return | +24.12% | -0.01% |
| 1-year return | +44.68% | +8.64% |
| 5-year return | -22.32% | -38.62% |
| P/E ratio (TTM) | 40.11 | 237.06 |
| Forward P/E | 13.65 | 65.36 |
| EPS (TTM) | $5.63 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $738.26M |
| Revenue growth (YoY) | +2.22% | +16.36% |
| Net income (latest FY) | $1.29B | $48.89M |
| Gross margin | 75.69% | 52.32% |
| Operating margin | — | 7.47% |
| Net margin | 13.07% | 6.62% |
| 52-week high | $230.49 | $198.87 |
| 52-week low | $138.00 | $100.99 |
| Distance from 52-week high | -2.02% | -12.98% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +5.46% | +12.65% |
| Average volume | 1.06M | 1.18M |
| Shares outstanding | 147.75M | 63.49M |
| Employees | 7,500 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biogen is about 3.0 times larger than Repligen by market value ($33.37B vs $10.99B).
- BIIB has outperformed RGEN by 36.0 percentage points over the past year.
- Repligen trades at a higher earnings multiple (237.1x vs 40.1x trailing P/E).
- Biogen is more profitable, keeping 13.1 cents of every revenue dollar as net income versus 6.6 cents for Repligen.
- Repligen grew revenue faster in its latest fiscal year (+16.36% vs +2.22%).
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
BIIB vs RGEN FAQ
Which is bigger, Biogen or Repligen?
Biogen (BIIB) is larger, with a market capitalization of $33.37B compared with $10.99B for Repligen (RGEN).
Which stock has performed better over the past year, BIIB or RGEN?
BIIB returned +44.68% over the past 12 months, compared with +8.64% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIIB or RGEN?
BIIB has the lower trailing P/E at 40.1, versus 237.1 for RGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biogen and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.